Keros Therapeutics' Phase 1 Clinical Trial Of KER-065 Achieves Key Objectives

(RTTNews) - Keros Therapeutics, Inc. (KROS), Monday announced the topline data from the Phase 1 clinical trial of KER-065 in healthy volunteers, showing its therapeutic potential for treatment of Duchenne muscular dystrophy and other neuromuscular indications.

The trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics. It also showed that KER-065 was generally well-tolerated, with no serious adverse events or dose-limiting toxicities reported.

The topline data further demonstrated that KER-065 increased bone specific alkaline phosphate and adiponectin during the trial, while decreasing C-Terminal Telopeptide and leptin in the participants.

Additionally, improvement in body composition with increase in bone mineral density and muscle mass, and decrease in fat mass were noted during the study.

Following this, the company plans to advance KER-065 into a Phase 2 clinical trial in the first quarter of 2026. Also, it plans on engaging with regulatory authorities, starting in the third quarter of 2025.

On Friday, Keros' stock closed at $10.79, down 1.82 percent on the Nasdaq.